Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
ABSTRACT
Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.
Top-30
Citations by journals
2
4
6
8
10
12
|
|
Frontiers in Immunology
11 publications, 4.93%
|
|
Scientific Reports
8 publications, 3.59%
|
|
Antimicrobial Agents and Chemotherapy
7 publications, 3.14%
|
|
Nature Communications
6 publications, 2.69%
|
|
Viruses
5 publications, 2.24%
|
|
International Journal of Molecular Sciences
5 publications, 2.24%
|
|
Journal of Virology
4 publications, 1.79%
|
|
Pharmacology and Therapeutics
4 publications, 1.79%
|
|
Frontiers in Microbiology
3 publications, 1.35%
|
|
Journal of Nanobiotechnology
3 publications, 1.35%
|
|
Expert Opinion on Pharmacotherapy
3 publications, 1.35%
|
|
Antiviral Research
3 publications, 1.35%
|
|
mAbs
3 publications, 1.35%
|
|
Science
3 publications, 1.35%
|
|
Antibodies
2 publications, 0.9%
|
|
Microorganisms
2 publications, 0.9%
|
|
Frontiers in Pharmacology
2 publications, 0.9%
|
|
Journal of Biological Chemistry
2 publications, 0.9%
|
|
Cell Reports
2 publications, 0.9%
|
|
iScience
2 publications, 0.9%
|
|
International Journal of Biological Macromolecules
2 publications, 0.9%
|
|
Advanced Drug Delivery Reviews
2 publications, 0.9%
|
|
Vaccine
2 publications, 0.9%
|
|
Cell
2 publications, 0.9%
|
|
International Journal of Pharmaceutics
2 publications, 0.9%
|
|
Biochimica et Biophysica Acta - General Subjects
2 publications, 0.9%
|
|
Advanced Therapeutics
2 publications, 0.9%
|
|
Advances in Experimental Medicine and Biology
2 publications, 0.9%
|
|
Expert Opinion on Investigational Drugs
2 publications, 0.9%
|
|
2
4
6
8
10
12
|
Citations by publishers
5
10
15
20
25
30
35
40
45
50
|
|
Elsevier
49 publications, 21.97%
|
|
Springer Nature
45 publications, 20.18%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
19 publications, 8.52%
|
|
Cold Spring Harbor Laboratory
19 publications, 8.52%
|
|
Taylor & Francis
18 publications, 8.07%
|
|
Frontiers Media S.A.
18 publications, 8.07%
|
|
American Society for Microbiology
12 publications, 5.38%
|
|
Wiley
8 publications, 3.59%
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 1.79%
|
|
SAGE
2 publications, 0.9%
|
|
Public Library of Science (PLoS)
2 publications, 0.9%
|
|
Oxford University Press
2 publications, 0.9%
|
|
American Physiological Society
2 publications, 0.9%
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.9%
|
|
The American Association of Immunologists
1 publication, 0.45%
|
|
Bentham Science
1 publication, 0.45%
|
|
Future Medicine
1 publication, 0.45%
|
|
Microbiology Society
1 publication, 0.45%
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.45%
|
|
KeAi Communications Co.
1 publication, 0.45%
|
|
American Chemical Society (ACS)
1 publication, 0.45%
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.45%
|
|
Pleiades Publishing
1 publication, 0.45%
|
|
Publishing House OKI
1 publication, 0.45%
|
|
eLife Sciences Publications
1 publication, 0.45%
|
|
Annual Reviews
1 publication, 0.45%
|
|
Saint Petersburg Pasteur Institute
1 publication, 0.45%
|
|
Spandidos Publications
1 publication, 0.45%
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.45%
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.